GAITHERSBURG, MD--(Marketwire - May 2, 2011) - Montgomery County Executive Isiah Leggett joined this morning with Dr. Ken Carter, President & CEO, Noble Life Sciences, Jennie M. Forehand, Maryland State Senator, District 17, Dr. Judith Britz, Executive Director, Maryland Biotechnology Center, and Ms. Ann Humphrey, on behalf of U.S. Congressman Chris Van Hollen and other public and private sectors guests to celebrate the official opening of Noble Life Sciences' new 6,000 square foot office and laboratory facility at 22 Firstfield Road in Gaithersburg, Maryland.
"The story of Noble Life Sciences is one we never tire of telling here in Montgomery County," said Leggett. "Dr. Carter directed the gene mapping initiative at Human Genome Sciences, Inc., for several years, then co-founded Avalon Pharmaceuticals, served as its CEO for ten years, took the company public and oversaw its successful merger with Clinical Data, Inc. -- even helping to get Clinical's sister company to move to the County. It's this type of business-savvy, serial biotech entrepreneur that has helped Montgomery County emerge as one of the nation's leading biotech hubs with some 330 biotech companies. I congratulate Ken and his team on this latest, successful venture."
Founded in 2010 and originally located in the County's Shady Grove Innovation Center, Noble Life Sciences is a provider of preclinical research services to the pharmaceutical and biotechnology industries.
"Our initial location in the County's Shady Grove Innovation Center allowed us to focus on growing the business and enabled us to move into this great new, expanded Gaithersburg facility," said Dr. Carter. "The concentration of pharmaceutical and biotechnology companies, leading academic institutions and federal agencies found in Maryland, and in particular Montgomery County, made our decision easy to locate our new facility here. We look forward to many years of growth and success in the County."
Noble received a $50K grant from the Montgomery County Economic Development Fund for equipment and a $200K translational research award from the Maryland Biotechnology Center. The company has five current, full-time employees and plans to add 25 new jobs over the next three years.
About Noble Life Sciences:
Noble Life Sciences provides a continuum of preclinical research services including preclinical experimental design and testing, disease models, selection and validation of biomarkers for personalized medicine, and vivarium services. With deep expertise in cancer drug development, the company offers access to their top scientists and works collaboratively with researchers in pharmaceutical, biotechnology, and diagnostic companies as well as those in academic and government institutions to deliver relevant, actionable information needed to expedite preclinical research and guide clinical development. For more information about Noble Life Sciences, visit www.noblelifesci.com.